Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPY130
- Development stage
- Preclinical
- Lead developer
- Spyre Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
SPY130 is a next-generation, bispecific monoclonal antibody combination therapy in preclinical development for inflammatory bowel diseases, particularly ulcerative colitis. It consists of two engineered antibodies—SPY001 and SPY003—formulated together to provide extended half-life and subcutaneous administration. The drug targets both the α4β7 integrin (via SPY001) and interleukin 23 (IL-23, via the p19 subunit targeted by SPY003), aiming to deliver dual inhibition of key inflammatory pathways implicated in IBD pathogenesis. This rational combination is designed to maximize efficacy with less frequent dosing compared to current therapies. The program is being developed by Paragon Therapeutics and Spyre Therapeutics[1][2][3].
- Brand names
- SPY001SPY-001SPY 001SPY003SPY-003SPY 003SPY001 + SPY003
- Other names
- PR022PR-022PR 022
02
Targets
α4β7 (Integrin alpha-4 beta-7 heterodimer)IL-23 (Interleukin-23)
Beyond the preview
Go deeper on SPY130.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPY130.